sorafenib has been researched along with mitomycin in 2 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (mitomycin) | Trials (mitomycin) | Recent Studies (post-2010) (mitomycin) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 12,893 | 1,738 | 2,808 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Borner, M; Candinas, D; Dufour, JF; Heim, MH; Helbling, B; Hoppe, H; Kickuth, R; Maurhofer, O; Saar, B; Szucs-Farkas, Z | 1 |
1 review(s) available for sorafenib and mitomycin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for sorafenib and mitomycin
| Article | Year |
|---|---|
Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study.
Topics: Antineoplastic Agents; Antineoplastic Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Catheters, Indwelling; Chemoembolization, Therapeutic; Combined Modality Therapy; Doxorubicin; Humans; Liver Neoplasms; Mitomycin; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |